Target intelligence / Profile preview

Vibrio cholerae O1 antigen

Molecular classification
Other (Bacterial surface polysaccharide), Antigen
01

Overview

The **Vibrio cholerae O1 antigen**, also known as the lipopolysaccharide (LPS) O-specific polysaccharide, is a carbohydrate structure located on the outer membrane surface of *Vibrio cholerae* strains belonging to serogroup O1—the primary cause of epidemic/pandemic human cholera worldwide[2][4]. The structure consists mainly of repeating perosamine-containing oligosaccharides that define two main serotypes—Ogawa and Inaba—based on subtle chemical differences such as methylation patterns at terminal residues[5][7]. This surface-exposed molecule serves several key roles:\n\n> \"The *Vibrio cholerae* lipopolysaccharide O1 antigen is a major target of bacteriophages and the human immune system... [and] is critical for infectivity\"[1].\n\nIt acts as an essential virulence factor required for colonization/infection; it also functions as a receptor for certain lytic bacteriophages that specifically bind these structures during infection cycles.[3] The high immunogenicity makes it central in current vaccine formulations aiming to elicit protective antibodies capable of neutralizing diverse clinical isolates.[7] However, phase-variable expression controlled by genes such as manA/wbeL allows bacterial populations flexibility under selective pressure from host immunity or phage predation.[1]\n\nIn summary, **Vibrio cholerae O1 antigen/LPS-O-SP is an essential bacterial surface carbohydrate serving both pathogenicity/immune evasion functions—and remains one of microbiology’s best-characterized targets for diagnostics, therapeutics, phage therapy research, and rational vaccine design.

Other names
V. cholerae O1 antigenLipopolysaccharide (LPS) O1 antigenO-specific polysaccharide (O-SP) of V. cholerae O1Ogawa/Inaba serotype determinant (depending on structural variant)
02

Mechanism of action

For drugs/vaccines targeting this molecule:\n- Induction of protective antibody responses that recognize and neutralize V. cholerae by binding to its surface-exposed LPS/O-antigen, blocking colonization or promoting opsonophagocytosis[7].\nFor phages:\n- Adsorption/attachment via specific recognition of the O-antigen as a cell-surface receptor, leading to infection/lysis of bacteria[3].

03

Biological functions

Immune response modulation (major epitope for antibody recognition)Phage receptor functionVirulence factor contributing to infectivity
04

Disease associations

Infection (Cholera)
05

Safety considerations

Antigenic variation can lead to immune evasion by bacteria, potentially reducing vaccine efficacy over time due to phase variation in biosynthetic genes like manA and wbeL[1][3].Structural heterogeneity between serotypes Ogawa and Inaba may require broad coverage in vaccines.Phase variation can generate subpopulations lacking full expression of the target epitope, complicating both natural immunity and vaccine-induced protection[1].
06

Interacting drugs

Cholera vaccines containing killed or attenuated V. cholerae (e.g., Oral killed whole-cell vaccines containing LPS antigens)

1 more in the full profile.

07

Biomarkers

Antibodies against V. cholerae O1 LPS/O-antigen

Beyond the preview

Go deeper on Vibrio cholerae O1 antigen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vibrio cholerae O1 antigen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call